2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

Citi initiated coverage of Regeneron (REGN) with a Neutral rating and $895 price target Multiple clinical data readouts should “keep ...

Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market The condition ...

According to Parikh, diabetic retinopathy is the leading cause of blindness and severe vision loss among working-age people ...

For all three outcomes -- dementia, stroke, and late-life depression -- the median follow-up was 12.5 years. During follow-up ...

Regeneron (REGN) Pharmaceuticals announced new and updated data from its hematology pipeline will be shared across 23 abstracts at the American Society of Hematology, ASH, 2024 Annual Meeting, taking ...

Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Sensei Biotherapeutics is laying off 46% of its workforce as the cancer-focused biotech looks to preserve cash to take its ...

TARRYTOWN, N.Y., Nov. 11, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) will webcast management participation as follows: • Jefferies London Healthcare Conference at 11:00 a.m. BST (6:00 a.m. ET) on ...

US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as ...

As with many other companies Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) makes use of debt. But should shareholders be worried about its use of debt? Generally speaking, debt only becomes a real ...